In this issue:
- Neoadjuvant immunotherapy in dMMR colon cancer
- Nivolumab + relatlimab for MSI-H/dMMR mCRC
- Cetuximab + FOLFOXIRI for unresectable colorectal liver metastases
- Oxaliplatin adjuvant duration and post-treatment fall-related injury and fracture
- Adjuvant COX-2 inhibition in PIK3CA-activated colon cancer
- Durvalumab + oleclumab, chemotherapy and bevacizumab in MSI-stable mCRC
- Microsatellite instability in mismatch repair proficient CRC
- ctDNA gene alterations after panitumumab and chemotherapy
- Microbiota composition effect on immunotherapy outcomes
- Population health economic impact of new CRC treatments
Please login below to download this issue (PDF)